With the recent Amarin proposed settlement, the non-prosecution of a medical device company and its CEO, and the removal of a Warning Letter from FDA’s website relating to off-label promotion, it’s a fair question to ask “what’s going on?” Without clear guidance from the Food and Drug Administration, life science companies are struggling to decide how best to approach off-label communications, if at all.
Register now to join AGG attorney, Alan Minsk, for a complimentary, one-hour webinar as they summarize some of the latest developments, address issues for companies to consider as they evaluate next steps internally, and answer questions from attendees. Please submit questions in advance on the registration form.
Credits: This webinar is pending CLE credit approval by the State Bar of Georgia.
Please direct any questions regarding the webinar to Tracey Chapman, 404.870.5684.